Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vora, A.
Right arrow Articles by Raina, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vora, A.
Right arrow Articles by Raina, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1833-1834, 2002
© 2002 European Society for Medical Oncology

Letters to the Editor

Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase

A. Vora, M. Bhutani*, A. Sharma and V. Raina

Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

*E-mail: manishabhutani@hotmail.com

The first 10% of the full text of this article appears below.

Signal transduction inhibitor 571 (STI 571), a potent and selective inhibitor of the tyrosine kinase activity of BCR–ABL, is an important advance in the treatment of chronic myelogenous leukemia (CML) patients in the advanced phase of disease or those with chronic phase (CP) intolerant or resistant to interferon (IFN) therapy [1–3]. Given at the dose of 400–600 mg p.o. daily, STI . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
G. Krishnan, K. D'Silva, and A. Al-Janadi
Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma
J. Clin. Oncol., May 10, 2008; 26(14): 2406 - 2408.
[Full Text] [PDF]